{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-126753","form_type":"8-K","ticker":"RANI","cik":"0001856725","company_name":"Rani Therapeutics Holdings, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.096755+00:00","generated_at":"2026-05-30T00:37:26.670180+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rani Therapeutics Q3 net loss $12.7M; cash $30.4M extended into Q3 2025","bullets":["Net loss of $12.7M for Q3 2024, compared to $18.3M in Q3 2023; includes $4.1M stock-based comp.","Cash, equivalents and marketable securities $30.4M as of Sep 30, 2024; runway extended into Q3 2025.","Completed two equity offerings for total gross proceeds of ~$20.0M in July and October 2024.","New preclinical PK data supports oral delivery of GLP-1/GIP/glucagon triagonist via RaniPill platform.","Phase 1 trial of RT-114 (GLP-1/GLP-2 dual agonist) for obesity expected to start in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-126753","json":"https://secwatch.observer/filing/0000950170-24-126753.json","markdown":"https://secwatch.observer/filing/0000950170-24-126753.md","text":"https://secwatch.observer/filing/0000950170-24-126753.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1856725/000095017024126753/0000950170-24-126753-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1856725/000095017024126753/rani-20241114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:37:26.670180+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}